Tuberculosis Vaccine

This page contains recent news articles, when available, and an overview of Tuberculosis Vaccine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on Tuberculosis Vaccine

[an error occurred while processing this directive]

News: Tuberculosis Vaccine

Joint Ventures/Cooperation/Collaboration Vaccine formulated with ...  -  Feb 13, 2008
news aktuell (Pressemitteilung),Intercell AG today announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens

Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis  -  Feb 13, 2008
PR Newswire (press release),...has granted sanofi pasteur a license to its technology with regard to the use of certain fusion proteins in the development of a tuberculosis vaccine.

Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis  -  Feb 13, 2008
Juraforum.de,SSI has granted sanofi pasteura license to its technology with regard to the use of certain fusionproteins in the development of a tuberculosis vaccine.

Sanofi Pasteur Working on New BCG Booster  -  Feb 19, 2008
FDA news (subscription),...has signed an agreement with the Statens Serum Institut (SSI) of Denmark for the development and marketing of a new tuberculosis vaccine.

Environmental sanitation controls tuberculosis  -  Feb 12, 2008
Sun St.Kitts/Nevis,These healthy traits, according to Martin, work effectively with the tuberculosis vaccine. The anti-TB vaccine (BGG) is given as part of the national

Crucell Announces Fourth Quarter and Full Year 2007 Results  -  Feb 12, 2008
FOXBusinessC6(R) Technology-Based Tuberculosis Vaccine (in collaboration with the Aeras Foundation) has been completed. The results of the trial indicate that the

TB is a 'Human Disgrace  -  Feb 11, 2008
AllAfrica.com,Speaking at the SA Tuberculosis Vaccine Initiative symposium in Cape Town, Dr. Marcos Espinal, Executive Secretary of the Stop TB Partnership, described TB

Bacilligen, Inc. Files Patent Applications on BVS Recombinant  -  Jan 30, 2008
Ad-Hoc-News (Pressemitteilung),...the company is focused on the bladder cancer application, rMB can also serve as a vector for delivery of vaccine antigens and as a tuberculosis vaccine.

Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp ...  -  Feb 12, 2008
PR Newswire (press release),SSI (to develop a new tuberculosis vaccine) and with Crucell (in monoclonal rabies antibodies), plus an alliance with the Institut Pasteur in malaria.

Aeras and Crucell Announce Start of a Tuberculosis Vaccine ...  -  Dec 20, 2007
FOX NewsC6(R)-based tuberculosis vaccine. Crucell and Aeras also announced the launch of a new Phase I BCG-Ad35 prime boost clinical trial of the unique

Crucell to start tuberculosis vaccine clinical trials in US  -  Dec 20, 2007
CNNMoney.com21, 2007 (Thomson Financial delivered by Newstex) -- Crucell (NASDAQ:CRXL) NV said it will start clinical trials for a tuberculosis vaccine in the US,

Aeras and Crucell Announce Start of a  -  Dec 20, 2007
Ad-Hoc-News (Pressemitteilung),Aeras and Crucell Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras commits a further USD 5 million to the development of

Statens Serum Institut (SSI), Intercell (ICLL), and Aeras Global ...  -  Dec 4, 2007
PharmaLive.com (press release),Â» The vaccine is a new candidate from a group of subunit vaccines against TB produced by SSI and aiming to boost the activity of the existing BCG vaccine.

TB treatment pays off, World Bank report finds  -  Dec 12, 2007
Canada.com,A new tuberculosis vaccine has shown promise in animal studies, researchers said on Wednesday, raising hope it might replace the current vaccine that has

Amsterdam shares close near highs buoyed by optimistic Wall Street ...  -  Dec 21, 2007
CNNMoney.comCrucell (NASDAQ:CRXL) strengthened 0.89 pct to 11.35 eur after the company announced that tuberculosis vaccine clinical trials starting in the US.

Amsterdam midday shares broadly up as S&P futures point to ...  -  Dec 21, 2007
CNNMoney.comCrucell (NASDAQ:CRXL) fell 0.53 pct to 11.19 eur, investors unimpressed by news of new tuberculosis vaccine clinical trials starting in the US.

Intercell Announces Launching of Phase I Clinical Trials of TB Vaccine  -  Dec 6, 2007
MedIndia,Austrian vaccine developer Intercell on Tuesday announced that it has launched Phase I clinical trials of a new preventive tuberculosis vaccine,

Vienna shares close lower, led by financials, OMV adds to pressure ...  -  Dec 4, 2007
Forbes,Intercell gained 1.83 pct to 27.24 eur on news the vaccine company has started phase I clinical trials for its prophylactic tuberculosis vaccine.

TB tests sometimes erroneous  -  Oct 3, 2007
Fort Wayne Journal Gazette,Potential sources for false-positive results include previous administration of bacille Calmette-Guirin, a tuberculosis vaccine, especially if itâ€™s been

News source: Business Wire  -  Sep 24, 2007
Genetic Engineering News (press release),Historical context: observations of bladder cancer patients; the tuberculosis vaccine; spontaneous regression of metastatic melanoma.

Investigador pÃ³s-doutorado  -  Sep 14, 2007
Naturlink,In the framework of the European Project â€œA new approach for developing a less Immunosuppressive Vaccine for Tuberculosis (ImmunoVacTB)â€?, one postdoctoral

Male Circumcision - Govt Not Ready, Urges Self-Initiative  -  Sep 3, 2007
AllAfrica.com,..."The efficacy of BCG, the tuberculosis vaccine is 33%, but don't we support it?" Kajimba, who is the senior presidential advisor of HIV/Aids, asked.

Partners off the gridiron  -  Aug 31, 2007
Denver Post,They created a tuberculosis vaccine. They charted a genetic map to identify precisely which drugs and in what doses work for an individual.

TB vaccine shows promise  -  Aug 1, 2007
Canada.com,A new tuberculosis vaccine has shown promise in animal studies, researchers said on Wednesday, raising hope it might replace the current vaccine that has

Lettuce As Anti-Tuberculosis Vaccine  -  Jun 19, 2007
Russia-InfoCenter,Institute of Physical and Chemical Biology of Moscow State University have developed a technology for producing anti-tuberculosis vaccine from plants.

Intercell Shares Rise On Novartis Pact, $366M Committed Cash  -  Jul 3, 2007
BioWorld Online,It has entered the clinic in one partnered program so far, as part of a tuberculosis vaccine in development at the Copenhagen, Denmark-based Statens Serum

* Intercell to receive upfront payment of EUR 270 ($ 360) million ...  -  Jul 1, 2007
Finanztreff,These collaborations include - amongst others - a Tuberculosis vaccine partnered with the Danish Statens Serum Institut, which has successfully concluded

Let's draw the best lesson  -  Jun 18, 2007
Financial Express.bd,The people belonging to the proactive group will take the anti-tuberculosis vaccine and will thus ward off the risk of having the deadly disease.

Local Lawmaker Pushes For New Tuberculosis Vaccine  -  05 Jun 2007
WTOV9.com,In the wake of a recent tuberculosis scare, some US lawmakers are urging drug manufactures to speed up their search for new tuberculosis vaccines.

CSU developing new tuberculosis vaccine  -  May 31, 2007
9NEWS.com,FORT COLLINS â€“ In the fight against tuberculosis, CSU is a major player. After receiving millions of dollars from the federal government to study the

COLORADO STATE UNIVERSITY DEVELOPS UNIQUE TUBERCULOSIS VACCINE ...  -  May 30, 2007
Colorado State University (press release),Preliminary evidence shows that the vaccine has promise of working after exposure to tuberculosis, which no other tuberculosis vaccine in current

â€¢ Case researchers focusing on finding tuberculosis vaccine  -  May 29, 2007
Cleveland Plain Dealer,For 14 years, more than half of the global AIDS pandemic, a Cleveland-led research project has explored ways of treating tuberculosis with standard drugs.

Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine ...  -  May 12, 2007
PipelineReview.com (press release),The South African Tuberculosis Vaccine Initiative is located in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town

Intercell AG announces Q1 results and update on development programs:  -  May 13, 2007
FinanzNachrichten.de,IC31TM, which is used as adjuvant in a Tuberculosis vaccine partnered with SSI, delivered an outstanding profile in a Phase I study completed in Q1 2007.

TB Clinical Trials Begin In South Africa  -  May 13, 2007
Vaccine Rx (press release),...the South African Tuberculosis Vaccine Initiative recently made it known that Phase I of the clinical trials for a new tuberculosis vaccine would be

Intercell's losses cut and revenues soar in first quarter  -  May 14, 2007
Pharma Times (subscription),It added that IC31, which is used as adjuvant in a tuberculosis vaccine partnered with SSI, has delivered "an outstanding profile in a Phase I study" which

Novel tuberculosis vaccine shows promising immunogenicity and ...  -  Mar 15, 2007
PipelineReview.com (press release),The Danish Statens Serum Institut (SSI) and Intercell report promising data from a phase I clinical trial with a tuberculosis (TB) subunit vaccine;

Intercell AG: Novel tuberculosis Vaccine Shows Promising ...  -  Mar 15, 2007
PharmaLive.com (press release),COPENHAGEN, Vienna, March 14, 2007 â€“ Statens Serum Institut (SSI) and Intercell announced today that their collaborative novel tuberculosis (TB) vaccine is

euro adhoc: Intercell AG / other / Novel tuberculosis vaccine ...  -  Mar 14, 2007
euro adhoc (Pressemitteilung),...-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc.

Novel tuberculosis vaccine shows promising immunogenicity and ...  -  Mar 14, 2007
news aktuell (Pressemitteilung),14.03.2007 - 19:05 Uhr, Intercell AG [Pressemappe] -------------------------------------------------------------------------------- Disclosure announcement

euro adhoc: Intercell AG / other / Novel tuberculosis vaccine ...  -  Mar 14, 2007
Finanztreff,Copenhagen (Denmark)/Vienna (Austria), March 14, 2007 - Statens Serum Institut (SSI) and Intercell announced today that their collaborative novel

Intercell's/SSI's new vaccine proved safe in phase I clinical trial  -  Mar 15, 2007
Forbes,VIENNA (AFX) - Austrian bio-tech company Intercell and Danish Statens Serum Institut (SSI) said that their new collaborative tuberculosis vaccine proved

Intercell Shares Jump After Vaccine Report  -  Mar 15, 2007
Reuters.uk,VI: Quote, Profile , Research) rose as much as 11 percent on Thursday after the company reported promising results for a tuberculosis vaccine in a clinical

Persbericht Crucell - USD 5 mln voor TBC-vaccine  -  Mar 7, 2007
BNR Nieuwsradio,..."Aeras' commitment toward the development of a tuberculosis vaccine is highly commendable," said Crucell's Chief Scientific Officer, Dr. Jaap Goudsmit.

Aeras Commits $5M to Crucell for Continued TB Research  -  Mar 7, 2007
Genetic Engineering News (press release),...receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine.

Older vaccine may be better at preventing TB  -  Mar 18, 2007
India eNews.com,The older version of the vaccine used to prevent tuberculosis may be better at preventing the disease than the more commonly used modern medicines,

euro adhoc: Intercell AG / Financial Figures/Balance Sheet /  -  Mar 4, 2007
news aktuell (Pressemitteilung),...opportunities - Intercellâ€™s technologies Â» Data of Intercellâ€™s adjuvant (IC31TM) in clinical proof of concept study in Tuberculosis Vaccine (Phase I)

New Powdered Tuberculosis Vaccine May Lead to Life-Saving Nasal Spray  -  Feb 20, 2007
Scientific AmericanIf combined with other changes to the current tuberculosis vaccine, called BCG, the drying technique could help save hundreds of thousands of lives,

Harvard scientists partner to develop and distribute new ...  -  Feb 20, 2007
innovations report,Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the most common tuberculosis (TB)

Harvard scientists partner to develop and distribute new ...  -  Feb 17, 2007
AND,By (AND) - www.andnetwork.com. Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the

Spraying method developed for TB vaccine  -  Feb 20, 2007
Earthtimes.org20 US bioengineers and public-health researchers have developed a spraying method for delivering the most common tuberculosis vaccine.

Crucell announces fourth quarter and annual results 2006  -  Feb 12, 2007
Market Wire (press release)Tuberculosis: In October Crucell initiated a Phase I clinical trial of a recombinant tuberculosis vaccine in partnership with AERAS Global TB Vaccine

BILL GATES PRAISES UK ON AFRICA  -  Feb 6, 2007
African Echo,In 2004, the Bill & Melinda Gates Foundation donated Â£55m (US$103m) for the development of a tuberculosis vaccine - to the Aeras Global TB Vaccine

Tackling diseases that devastate the poor  -  Dec 1, 2006
Kansas City Star,Reed also brought together scientists from the institute, Corixa and GlaxoSmithKline to develop the world's first large-scale tuberculosis vaccine.

Family trying to cope with father's death  -  Dec 11, 2006
Monitor,Maria said. Her youngest daughter, Alondra, canâ€™t go to school because Maria canâ€™t afford the $18 tuberculosis vaccine. "That ...

Search the web for more resources on Tuberculosis Vaccine

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.